Extended Data Table 3 CLEVER DTC clearance at cycle 6 (original arm assignment) and cycle 12 (additional HCQ + EVE) by treatment and receptor subtype

From: Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial